Safety and Efficacy of a Mesenchymal Stem Cell Secretome Therapy (KPI-012) for Persistent Corneal Epithelial Defects: A Phase 1b Trial

Safety and Efficacy of a Mesenchymal Stem Cell Secretome Therapy (KPI-012) for Persistent Corneal Epithelial Defects: A Phase 1b Trial

Background: Persistent corneal epithelial defect (PCED) is a condition often refractory to conventional treatments. KPI-012 is a topical mesenchymal stem cell secretome therapy under investigation for PCED management. Objective: To assess the safety, tolerability, and corneal wound healing efficacy...

Full description

Saved in:
Bibliographic Details
Main Authors: Valeria Sánchez Huerta, MD, Hugo Quiroz-Mercado, MD, Enrique O. Graue-Hernández, MD, MSc, Alejandro Navas, MD, MSc, Spencer Alford, PhD, Darius Kharabi, JD, MBA, Stephen Pflugfelder, MD
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Current Therapeutic Research
Subjects:
cornea
corneal wound
diabetic
diseases of the ocular surface
keratitis
persistent corneal epithelial defects
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X25000244
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X25000244

Similar Items